Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Biology Reports"
DOI: 10.1007/s11033-018-4537-5
Abstract: Human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC) is an aggressive BC subtype characterized by HER2 overexpression/amplification. Genomic alterations of HER2 and others have been reported to be associated with, HER2 overexpression… read more here.
Keywords: response; response trastuzumab; trastuzumab; associated her2 ... See more keywords